Blood-Based Biomarkers Reshape Alzheimer’s and Neurodegenerative Care
Personalized briefing
Discovery of the day · Neurology
[Series] Fluid biomarkers in the evolving care landscape of Alzheimer’s disease and related disorders
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
Ultraprecise fluid biomarkers — notably blood phosphorylated tau 217 for Alzheimer’s disease and neurofilament light for frontotemporal dementia and amyotrophic lateral sclerosis — are now translating from research assays into routine clinical practice. The field has advanced through ultrasensitive immunoassays, multiplexing platforms, and high-specificity antibodies that achieve diagnostic performance approaching cerebrospinal fluid and PET-based measures, arriving just as amyloid-targeting therapies enter clinical availability. This convergence is directly actionable for your work: it positions blood-based proteomic panels as scalable tools for diagnostic assay deployment and longitudinal disease-activity monitoring, and creates a practical imperative to correlate these analytes with imaging, clinical scales, and sensor or wearable-derived endpoints for MS, Parkinson’s, and Alzheimer’s populations.
Novelty
74%
Rigor
82%
Significance
91%
Validity
83%
Clarity
90%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
